Acceleration of autoimmune diabetes in Rheb-congenic NOD mice with β-cell-specific mTORC1 activation

Biochemical and Biophysical Research Communications

Volumn 408, Issue 2, 2011, Pages 306-311

  Sasaki, Hirotomo ^a   Yasuda, Hisafumi ^a   Moriyama, Hiroaki ^a   Nakamura, Akira ^a   Shimizu, Mami ^a   Arai, Takashi ^a   Nagata, Masao ^a   Hara, Kenta ^a   Yokono, Koichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CFA; GLP 1; MTOR; NOD; Rheb; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN AUTOANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RHEB PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; HISTOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; INSULIN-SECRETING CELLS; MICE; MICE, CONGENIC; MICE, INBRED NOD; MONOMERIC GTP-BINDING PROTEINS; NEUROPEPTIDES; PROTEINS;

MUS;

EID: 79955648133     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.026     Document Type: Article

References (30)

1. Eisenbarth G.S. Type 1 diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 1986, 314:1360-1368.
2. Nakayama M., Abiru N., Moriyama H., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
3. Makino S., Kunimoto K., Muraoka Y., et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980, 29:1-13.
4. Zhang Z.J., Davidson L., Eisenbarth G., et al. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 1991, 88:10252-10256.
5. Daniel D., Wegmann D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA 1996, 93:956-960.
6. Huchings P.R., Cooke A. Comparative study of the protective effect afforded by intravenous administration of bovine or ovine insulin to young NOD mice. Diabetes 1995, 44:906-910.
7. Diabetes prevention Trial-type 1 diabetes Study Group, Effects of insulin in relatives of patients with type 1 diabetes mellitus, N. Engl. J. Med 346 (2002) 1685-1691.
8. Sreenan S., Pick A.J., Levisetti M., et al. Increased β-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999, 48:989-996.
9. Nir T., Melton D.A., Dor Y. Recovery from diabetes in mice by β cell regeneration. J. Clin. Invest. 2007, 117:2553-2561.
10. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
11. Hara K., Maruki Y., Long X., et al. Raptor, a binding partner of target of rapamycin (TOR) mediates TOR action. Cell 2002, 110:177-189.
12. Kim D.H., Sarbassov D.D., Ali S.M., et al. GbetaL, A positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 2003, 11:895-904.
13. Hara K., Yonezawa K., Kozlowski M.T., et al. Regulation of eIF-4EBP1 phosphorylation by mTOR. J. Biol. Chem. 1997, 272:26457-26463.
14. Avruch J., Hara K., Lin Y., et al. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 2006, 25:6361-6372.
15. Hamada S., Hara K., Hamada T., et al. Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia. Diabetes 2009, 58:1321-1332.
16. Serreze D.V., Chapman H.D., Varnum DS B., et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new " Speed congenic" Stock of NOD. Ig mu null mice. J. Exp. Med. 1996, 184:2049-2053.
17. Yu L., Robles D.T., Abiru N., et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl. Acad. Sci. USA 2000, 97:1701-1706.
18. Yasuda H., Jin Z., Nakayama M., et al. NO-mediated cytotoxicity contributes to multiple low-dose streptozotocin-induced diabetes but not to NOD diabetes. Diabetes Res. Clin. Pract. 2009, 83:200-207.
19. Norquay L.D., D'Aquino K.E., Opare-Addo L.M., et al. Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice. Endocrinology 2009, 150:4531-4540.
20. Shigeyama Y., Kobayashi T., Kido Y., et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol. Cell. Biol. 2008, 28:2971-2979.
21. Elghazi L., Balcazar N., Blandino-Rosano M., et al. Decreased IRS signaling impairs beta-cell cycle progression and survival in transgenic mice overexpressing S6K in beta-cells. Diabetes 2010, 59:2390-2399.
22. Ryu S., Kodama S., Ryu K., et al. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J. Clin. Invest. 2001, 108:63-72.
23. Kodama S., Kuhtreiber S.W., Fujimura S., et al. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 2003, 302:1223-1227.
24. Chong A.S., Shen J., Tao J., et al. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived β cell regeneration. Science 2006, 311:1774-1775.
25. Nishio J., Gaglia J.L., Turvey S.E., et al. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 2006, 311:1775-1778.
26. Suri A., Calderon B., Esparza T.J., et al. Immunological reversal of autoimmune diabetes without hematopoietic replacement of β cells. Science 2006, 311:1778-1780.
27. Okubo Y., Shimada A., Kanazawa Y., et al. Hyperplastic islets observed in " reversed" NOD mice treated without hematopoietic cells. Diabetes Res. Clin. Pract. 2008, 79:18-23.
28. Mori Y., Kodaka T., Kato T., et al. Critical role of IFN-gamma in CFA-mediated protection of NOD mice from diabetes development. Int. Immunol. 2009, 21:1291-1299.
29. Huszarik K., Wright B., Keller C., et al. Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice. J. Immunol. 2010, 185:5120-5129.
30. Xu G., Stoffers D.A., Habener J.F., et al. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rat. Diabetes 1999, 48:2270-2276.